It's Time For a Quick Look at Medical Properties Trust's Fundamentals.

By Kim Brooks • Sunday, November 19 12:05 • Permanent Link

More and more people are talking about Medical Properties Trust over the last few weeks. Is it worth buying the Specialty Real Estate Investment Trust stock at a price of $4.61? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Medical Properties Trust has moved -60.0% over the last year, and the S&P 500 logged a change of 15.0%
MPW has an average analyst rating of hold and is -38.53% away from its mean target price of $7.5 per share
Its trailing earnings per share (EPS) is $-0.06
Medical Properties Trust has a trailing 12 month Price to Earnings (P/E) ratio of -76.8 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $0.87 and its forward P/E ratio is 5.3
The company has a Price to Book (P/B) ratio of 0.33 in contrast to the S&P 500's average ratio of 2.95
Medical Properties Trust is part of the Real Estate sector, which has an average P/E ratio of 24.81 and an average P/B of 2.24
MPW has reported YOY quarterly earnings growth of -48.6% and gross profit margins of 1.0%
The company has a free cash flow of $531.73 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world's largest owners of hospital real estate with 441 facilities and approximately 44,000 licensed beds as of September 30, 2023. Since the end of the third quarter, the Company has sold four facilities and now owns approximately 43,000 licensed beds in nine countries across three continents. MPT's financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.